These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 20816027

  • 1. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [Abstract] [Full Text] [Related]

  • 2. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM, Aboujaoude E, Gamel NN.
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [Abstract] [Full Text] [Related]

  • 3. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK.
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [Abstract] [Full Text] [Related]

  • 4. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
    Sahraian A, Bigdeli M, Ghanizadeh A, Akhondzadeh S.
    J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
    [Abstract] [Full Text] [Related]

  • 5. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG.
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [Abstract] [Full Text] [Related]

  • 6. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.
    Van Ameringen M, Mancini C, Patterson B, Bennett M.
    Depress Anxiety; 2006 Jul; 23(1):1-5. PubMed ID: 16178009
    [Abstract] [Full Text] [Related]

  • 7. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E.
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [Abstract] [Full Text] [Related]

  • 8. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Aboujaoude E, Barry JJ, Gamel N.
    J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
    [Abstract] [Full Text] [Related]

  • 9. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
    Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S.
    Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
    [Abstract] [Full Text] [Related]

  • 10. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [Abstract] [Full Text] [Related]

  • 11. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
    Rutrick D, Stein DJ, Subramanian G, Smith B, Fava M, Hasler G, Cha JH, Gasparini F, Donchev T, Ocwieja M, Johns D, Gomez-Mancilla B.
    Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
    [Abstract] [Full Text] [Related]

  • 12. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Bruno A, Micò U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR.
    J Psychopharmacol; 2012 Nov; 26(11):1456-62. PubMed ID: 22351381
    [Abstract] [Full Text] [Related]

  • 13. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [Abstract] [Full Text] [Related]

  • 14. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E, Dell'Osso B.
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [Abstract] [Full Text] [Related]

  • 15. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
    Sarris J, Oliver G, Camfield DA, Dean OM, Dowling N, Smith DJ, Murphy J, Menon R, Berk M, Blair-West S, Ng CH.
    CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
    [Abstract] [Full Text] [Related]

  • 16. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M.
    BMC Psychiatry; 2022 Jan 12; 22(1):34. PubMed ID: 35022014
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.
    J Clin Psychiatry; 2003 Jun 12; 64(6):640-7. PubMed ID: 12823077
    [Abstract] [Full Text] [Related]

  • 18. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA.
    J Clin Psychopharmacol; 2011 Apr 12; 31(2):174-9. PubMed ID: 21346614
    [Abstract] [Full Text] [Related]

  • 19. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D, de Geus F, van Megen HJ, Westenberg HG.
    J Clin Psychiatry; 2004 Aug 12; 65(8):1040-8. PubMed ID: 15323587
    [Abstract] [Full Text] [Related]

  • 20. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM, Ringold AL, Elliott MA.
    J Clin Psychiatry; 2000 Jul 12; 61(7):514-7. PubMed ID: 10937610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.